PATENT CLAIM ANALYSIS

Application Number: 15957457
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "131100"]

Abstract:
The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

Claim (Index 19):
A kit comprising a composition comprising at least 10 but less than 50 contiguous nucleobase residues of SEQ ID NO. 1, wherein the contiguous nucleobase residues comprise the nucleobase at position 256 within rs5745994 (SEQ ID NO. 1), and wherein the contiguous nucleobase residues are connected to a detectable molecule comprising a fluorophore, and a primer pair configured to hybridize to 10 contiguous nucleobases of SEQ ID NO. 1 spanning nucleobase 256.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 91.0
- Lexical Diversity: 1.48485
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13840779', '12851517', '15030790', '13322863', '15571734']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6613449689489357
- 35 USC 102 Novelty (BERT): 0.4899653378303433
- Combined Prediction Score: 0.6442070058370765
- Mean Citation Score: 146.174042
- Max Citation Score: 165.7468
- Similarity Product: 107.26405588212012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test